Impact ofMACC1 on human malignant glioma progression and patients' unfavorable prognosis

Neuro-Oncology

Volumn 15, Issue 12, 2013, Pages 1696-1709

  Hagemann, Carsten ^a   Fuchs, Steffen ^a   Monoranu, Camelia M ^a   Herrmann, Pia ^b   Smith, Janice ^b   Hohmann, Tim ^c   Grabiec, Urszula ^c   Dehghani, Faramarz ^c   Löhr, Mario ^a   Ernestus, Ralf Ingo ^a   Vince, Giles H ^a   Stein, Ulrike ^b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Astrocytoma WHO grade II; Glioblastoma multiforme; MACC1; Prognostication; Progression

Indexed keywords

CRIZOTINIB; MACC1 PROTEIN; MESSENGER RNA; ONCOPROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG; MACC1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ADULT; AGED; ANIMAL TISSUE; ARTICLE; BRAIN SLICE; CANCER PROGNOSIS; CARCINOGENESIS; CELL INVASION; CELL MOTILITY; CELL PROLIFERATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; GLIOBLASTOMA; HIPPOCAMPUS; HUMAN; HUMAN CELL; MALE; MIDDLE AGED; NONHUMAN; PRESCHOOL CHILD; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; SLICE CULTURE; TIME; TUMOR GROWTH; YOUNG ADULT; ADOLESCENT; ANIMAL; APOPTOSIS; ASTROCYTOMA WHO GRADE II; BRAIN TUMOR; C57BL MOUSE; CANCER GRADING; CELL MOTION; DISEASE COURSE; ENZYME IMMUNOASSAY; FLOW CYTOMETRY; FOLLOW UP; GENE EXPRESSION REGULATION; GENETICS; GLIOMA; MACC1; METABOLISM; MORTALITY; MOUSE; ORGAN CULTURE TECHNIQUE; PATHOLOGY; PROGNOSIS; PROGNOSTICATION; PROGRESSION; SURVIVAL RATE; TUMOR CELL CULTURE; VERY ELDERLY; WESTERN BLOTTING;

ASTROCYTOMA WHO GRADE II; GLIOBLASTOMA MULTIFORME; MACC1; PROGNOSTICATION; PROGRESSION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL MOVEMENT; CELL PROLIFERATION; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; NEOPLASM GRADING; ORGAN CULTURE TECHNIQUES; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84891890119     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not136     Document Type: Article

References (57)

1. Talmadge JE, Fidler IJ. AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res. 2010;70:5649-5669.
2. Hannahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674.
3. Stein U,WaltherW, Arlt F, et al.MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med. 2009;15:59-67.
4. Arlt F, Stein U. Colon cancer metastasis: MACC1 and Met as metastatic pacemakers. Int J Biochem Cell Biol. 2009;41:2356-2359.
5. Pichorner A, Sack U, Kobelt D, et al. In vivo imaging of colorectal cancer growth and metastasis by targeting MACC1 with shRNA in xenografted mice. Clin Exp Metastasis. 2012;29:573-583.
6. Kokoszynska K, Krynski J, Rychlewski L, Wyrwicz LS. Unexpected domain composition of MACC1 links METsignaling and apoptosis. Acta Biochim Pol. 2009;56:317-323.
7. Stein U, Dahlmann M,WaltherW.MACC1 - morethan metastasis? Facts and predictions about a novel gene. J Mol Med. 2010;88:11-18.
8. Stein U. MACC1 - A novel target for solid cancers. Expert Opin Ther Targets. 2013;17:1039-1052.
9. Galimi F,Torti D, Sassi F, et al. Genetic expression analysis ofMET,MACC1, and HGF in metastatic colorectal cancer: Response to Met inhibition in patient xenografts and pathologic correlations. Clin Cancer Res. 2011;17:3146-3156.
10. Kawamura M, Saigusa S, Toijama Y, et al. Correlation ofMACC1 and Met expression in rectal cancer after neoadjuvant chemoradiotherapy. Anticancer Res. 2012;32:1527-1531.
11. Shirahata A, Shinmura K, Kitamura Y, et al. MACC1 as a marker for advanced colorectal carcinoma. Anticancer Res. 2010;30:2689-2692.
12. Shirahata A, Sakata M, Kitamura Y, et al.MACC1 as amarker for peritoneal disseminated gastric carcinoma. Anticancer Res. 2010;30:3441-3444.
13. Chundong G, Uramoto H, Onitsuka T, et al. Molecular diagnosis of MACC1 status in lung adenocarcinoma by immunohistochemical analysis. Anticancer Res. 2011;31:1141-1145.
14. Shimokawa H, Uramoto H, Onitsuka T, et al. Overexpression of MACC1 mRNA in lung adenocarcinoma is associated with postoperative recurrence. J Thor Card Surg. 2011;141:895-898.
15. Qiu J, Huang P, Liu Q, et al. Identification ofMACC1 as a novel prognostic marker in hepatocellular carcinoma. J Transl Med. 2011;9:166.
16. Shirahata A, FanW, Sakuraba K, et al.MACC1 as a marker for vascular invasive hepatocellular carcinoma. Anticancer Res. 2011;31:777-780.
17. Reifenberger G, CollinsVP. Pathology and molecular genetics of astrocytic gliomas. J Mol Med. 2004;82:656-670.
18. CaveneeWK,FurnariFB,NaganeM,et al.Diffuselyinfiltratingastrocytomas. In: Kleihues, P, Cavenee,WK, eds. Pathology and Genetics of Tumors of the Nervous System.WHOClassification of Tumors. Lyon: IARC; 2000: 10-21.
19. Maher EA, Brennan C,Wen PY, et al. Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. Cancer Res. 2006;66:11502-11513.
20. Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol. 2007;170:1445-1453.
21. Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. Clin Cancer Res. 2013;19:764-772.
22. Stupp R, Hegi ME, MasonWP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459-466.
23. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996.
24. Moriyama T, Kataoka H, Koono M,Wakisaka S. Expression of hepatocyte growth factor/scatter factor and its receptor c-Met in brain tumors: evidence for a role in progression of astrocytic tumors. Int J Mol Med. 1999;3:531-536.
25. Laterra J, Rosen E,NamM, Ranganathan S, Fielding K, Johnston P. Scatter factor/hepatocyte growth factor expression enhances human glioblastoma tumorigenicity and growth. Biochim Biophys Res Commun. 1997;235:743-747.
26. Moriyama T, Kataoka H, Seguchi K, Tsubouchi H, Koono M. Effects of hepatocyte growth factor (HGF) onhumanglioma cells in vitro:HGFacts as a motility factor in glioma cells. Int J Cancer. 1996;66:678-685.
27. Nabeshima K, Shimao Y, Sato S, et al. Expression of c-Met correlates with grade of malignancy in human astrocytic tumours: An immunohistochemical study. Histopathology. 1997;31:436-443.
28. Yamamoto S, Wakimoto H, Aoyagi M, Hirakawa K, Hamada H. Modulation of motility and proliferation of glioma cells by hepatocyte growth factor. Jpn J Cancer Res. 1997;88:564-577.
29. Stein U, Smith J, Walther W, Arlt F. MACC1 controls Met. What a difference an Sp1 site makes. Cell Cycle. 2009;8:2467-2469.
30. Boardman LA. Overexpression ofMACCI leads to downstream activation of HGF/MET and potentiates metastasis and recurrence of colorectal cancer. Gen Med. 2009;1:36.
31. Kleihues P, Louis DN, Scheithauer BW, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol. 2002; 61:215-225.
32. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114:97-109.
33. Hagemann C, Meyer C, Stojic J, et al. High efficiency transfection of glioma cell lines and primary cells for overexpression and RNAi experiments. J Neurosci Methods. 2006;156:194-202.
34. Stojic J,Hagemann C,Haas S, et al. Expression ofmatrixmetalloproteinases MMP-1, MMP-11 and MMP-19 is correlated with the WHO-grading of human malignant gliomas. Neurosci Res. 2008;60:40-49.
35. Said HM, Hagemann C, Stojic J, et al. GAPDH is not regulated in human glioblastoma under hypoxic conditions. BMC Mol Biol. 2007;8:55.
36. Hagemann C, Anacker J, Gerngras S, et al. Expression analysis of the autosomal recessive primary microcephaly genes MCPH1 (microcephalin) and MCPH5 (ASPM, abnormal spindle like, microcephaly associated) in human malignant gliomas. Oncol Rep. 2008;20:301-308.
37. Abramoff MD, Magalhaes PJ, Ram SJ. Image processing with ImageJ. Biophotonics International. 2004;11:36-42.
38. Ebrahimi F, Koch M, Pieroh P, et al. Time dependent neuroprotection of mycophenolate mofetil: effects on temporal dynamics in glial proliferation, apoptosis, and scar formation. J Neuroinflammation. 2012;9:89.
39. Thévenaz P, Delgado-Gonzalo R, Unser M. The ovuscule. IEEE Trans Pattern Anal Mach Intell. 2011;33:382-393.
40. Zhang Y, Farenholtz KE, Yang Y, et al. Hepatocyte growth factor sensitizes brain tumors to c-Met kinase inhibition. Clin Cancer Res. 2013;19:1433-1444.
41. Rath P, Lal B, Ajala O, et al. In vivo c-Met pathway inhibition depletes human glioma xenografts of tumor-propagating stem-like cells. Transl Oncol. 2013;6:104-111.
42. Fu J,Wang YK, YangMT, et al. Mechanical regulation of cell function with geometrically modulated elastomeric substrates. Nat Methods. 2010;7:733-736.
43. Barnhart EL, Lee KC, Keren K, et al. An adhesion-dependent switch between mechanisms that determine motile cell shape. PloS Biol. 2011;9:e1001059.
44. Harada T, Baril P, Gangeswaran R, et al. Identification of genetic alterations in pancreatic cancer by the combined use of tissue microdissection and array-based comparative genomic hybridization. Br J Cancer. 2007;96:373-382.
45. MoroharaK, TajimaY, Nakao K, et al. Gastric and intestinal phenotypic cell marker expressions in gastric differentiated-type carcinomas: Association with E-cadherin expression and chromosomal changes. J Cancer Res Clin Oncol. 2006;132:363-375.
46. Tsiambas E, Manaios L, Papanikolopoulos C, et al. Chromogenic in situ hybridization analysis of epidermal growth factor receptor gene/chromosome 7 numerical aberrations in hepatocellular carcinoma based on tissue microarrays. Pathol Oncol Res. 2009;15:511-520.
47. Ubagi T, Matsuura S, Tauchi H, Itou K, Komatsu K. Comparative genomic hybridization analysis suggests a gain of chromosome 7p associated with lymph node metastasis in non-small cell lung cancer. Oncol Rep. 2001;8:83-88.
48. Zimmermann U, Feneux D, Mathey G, Gayral F, Bedossa P. Chromosomal aberrations in hepatocellular carcinomas: Relationship with pathological features. Hepatology. 1997;26:1492-1498.
49. Zojer N,DekanG,Ackermann J, et al. Aneuploidyofchromosome7 can be detected in invasive lung cancer and associated premalignant lesions of the lung by fluorescence in situ hybridization. Lung Cancer. 2000;28:225-235.
50. Loeper S, Romeike BFM, Heckmann N, et al. Frequent mitotic errors in tumor cells of genetically micro-heterogeneous glioblastomas. Cytogenet Cell Genet. 2001;94:1-8.
51. Rossi MR, La Duca J, Matsui S-I, Nowak NJ, Hawthorn L, Cowell JK. Novel amplicons on the short arm of chromosome 7 identified using high resolution arrayCGHcontain over expressed genes in addition to EGFR in glioblastoma multiforme. Genes Chromosomes Cancer. 2005;44:392-404.
52. Shapiro Jr. Genetic alterations associated with adult diffuse astrocytic tumors. Am J Med Genet. 2002;115:194-201.
53. Arslantas A, Artan S,Öner Ü, et al. Genomic alterations in low-grade, anaplastic astrocytomas and glioblastomas. Path Oncol Res. 2007;13:39-46.
54. Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401-404.
55. Arrieta O, Garcia E, Guevara P, et al. Hepatocyte growth factor is associated with poor prognosis of malignant gliomas and is a predictor for recurrence of meningioma. Cancer. 2002;94:3210-3218.
56. Lal B, Xia S, Abounader R, Laterra J. Targeting the c-Met pathway potentiates glioblastoma responses to g-radiation. Clin Cancer Res. 2005;11:4479-4486.
57. Wen PY, Schiff D, Cloughesy TF, et al. A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro-Oncol. 2011;13:437-446.